HSPA5 Antibody

What is HSPA5 and why is it significant for research?

HSPA5 is a 72.3 kilodalton endoplasmic reticulum chaperone protein that plays crucial roles in protein folding, ER stress response, and various cellular processes. Its significance in research stems from:

• Its involvement in multiple disease pathways including cancer progression, metastasis, and drug resistance

• Its role as a potential receptor for SARS-CoV-2 invasion

• Its function in endoplasmic reticulum stress responses and protein quality control

• Its emerging role in regulation of RNA alternative splicing

• Its association with immune infiltration in various cancer types

HSPA5 is ubiquitously expressed in normal tissues but significantly upregulated in 14 of 31 types of cancer tissues, making it an important research target for oncology studies .

What are the primary applications for HSPA5 antibodies in academic research?

HSPA5 antibodies are versatile tools with multiple research applications:

• Western blot detection of HSPA5 protein expression (typically observed at 74-80 kDa bands)

• Immunohistochemistry for tissue localization in both normal and pathological samples

• Immunoprecipitation for studying protein interactions and post-translational modifications

• Flow cytometry for cell surface HSPA5 detection

• Chromatin immunoprecipitation for transcriptional regulation studies

• RNA immunoprecipitation for investigating RNA-protein interactions

• Gene silencing validation experiments

For optimal results, each laboratory should determine ideal antibody dilutions for specific applications, as noted in reference materials .

How do I verify HSPA5 antibody specificity in experimental systems?

Methodological approach for HSPA5 antibody validation:

• Molecular weight verification: Confirm detection at the expected size (~74-80 kDa) in Western blot

• Positive control selection: Use validated cell lines like HeLa human cervical epithelial carcinoma or A20 mouse B cell lymphoma which consistently express HSPA5

• Cross-reactivity testing: Test antibody against recombinant proteins with similar sequences

• Gene silencing controls: Include HSPA5-silenced samples as negative controls

• Multiple antibody comparison: Test at least two different HSPA5 antibodies targeting different epitopes

• Tissue panel validation: Test against a panel of tissues with known HSPA5 expression patterns

Research data shows detection of specific bands for HSPA5 at approximately 80 kDa in Western blot and 74 kDa in Simple Western systems, which can serve as reference points for validation .

What experimental conditions affect HSPA5 antibody performance?

Several factors influence HSPA5 antibody performance:

Empirical testing with positive controls is essential for optimization in each experimental system.

How can I differentiate between endoplasmic reticulum HSPA5 and cell surface HSPA5?

Distinguishing cellular localization of HSPA5 requires specialized methodological approaches:

• Cell surface-specific labeling:

  • Use non-permeabilizing conditions in flow cytometry

  • Apply membrane-impermeable biotinylation reagents followed by streptavidin pull-down

  • Perform live-cell immunofluorescence at 4°C to prevent internalization

• Subcellular fractionation:

  • Isolate membrane fractions using sucrose gradient ultracentrifugation

  • Validate fraction purity with organelle markers (calnexin for ER, Na+/K+ ATPase for plasma membrane)

• Confocal microscopy with co-localization markers:

  • Use ER markers (e.g., PDI, calnexin) and membrane markers (e.g., WGA)

  • Perform Z-stack imaging for precise localization

Research indicates that under stress conditions, HSPA5 translocates to the cell surface where it binds numerous ligands and activates various signaling pathways . This translocation is particularly relevant in cancer cells and during SARS-CoV-2 infection, where cell surface HSPA5 serves as a potential viral entry point .

What approaches help resolve contradictory HSPA5 expression data across different cancer types?

Methodological strategies to address conflicting HSPA5 expression data:

• Multi-level analysis integration:

  • Compare mRNA expression (RNA-seq, qPCR) with protein expression (Western blot, IHC)

  • Analyze HSPA5 at genomic, transcriptomic, and proteomic levels

  • Cross-reference with epigenetic regulation data

• Standardized quantification protocols:

  • Use absolute quantification methods with recombinant protein standards

  • Implement digital pathology for IHC quantification

  • Apply consensus normalization protocols as used in HPA, GTEx, and FANTOM5 datasets

• Detailed sample stratification:

  • Classify samples by cancer stage, grade, and molecular subtypes

  • Account for treatment history and patient demographics

  • Analyze expression in context of tumor microenvironment

Research has demonstrated significant differences in HSPA5 expression across cancer stages. For example, HSPA5 expression was significantly higher in Stage IV compared to Stage I and Stage III in ACC, while in BLCA, expression was significantly higher in Stage III and Stage IV compared to Stage I+II .

What experimental design is optimal for investigating HSPA5's role in SARS-CoV-2 infection?

A comprehensive experimental approach should include:

• Binding interaction studies:

  • Surface plasmon resonance to determine binding affinities between HSPA5 and SARS-CoV-2 spike protein

  • Co-immunoprecipitation with HSPA5 antibodies to confirm physical interaction

  • Molecular docking validation focusing on domain III (C391-C525) and IV (C480-C488) regions of the receptor-binding domain

• Functional validation experiments:

  • HSPA5 knockdown/knockout studies in susceptible cell lines

  • Blocking experiments using anti-HSPA5 antibodies

  • Competitive inhibition assays with HSPA5 binding peptides

• Translocation dynamics assessment:

  • Live-cell imaging of HSPA5 trafficking during infection

  • Analysis of HSPA5-ACE2 co-localization, as ACE2 requires HSPA5 for cell surface translocation

• Variant comparison studies:

  • Compare binding affinities of HSPA5 with different SARS-CoV-2 variants (wildtype, delta, omicron)

  • Evaluate differences in receptor utilization across variants

Research indicates that the best binding site for HSPA5 is the cyclic nine amino acid residues (CNGVEGFNC) of region IV in the receptor-binding domain, and newer variants like 501.V2 and omicron are predicted to bind more tightly to HSPA5 than the wildtype .

How can I investigate post-translational modifications of HSPA5 using antibody-based techniques?

Methodological approach for studying HSPA5 post-translational modifications:

• Modification-specific antibodies:

  • Use antibodies specific to acetylated HSPA5 (targeting K353)

  • Employ anti-ubiquitin antibodies following HSPA5 immunoprecipitation

• Pharmacological interventions:

  • Apply histone deacetylase inhibitors (e.g., LBH589) to increase HSPA5 acetylation

  • Use proteasome inhibitors (e.g., MG132) to prevent degradation of ubiquitinated HSPA5

• Site-directed mutagenesis validation:

  • Compare wild-type HSPA5 with K353R mutants (which cannot be acetylated) in ubiquitination studies

  • Assess K352R mutants as controls

• Sequential immunoprecipitation:

  • First IP with anti-HSPA5, then probe with anti-modification antibodies

  • Perform the reverse: IP with anti-modification antibodies, then detect HSPA5

Research has shown that E1A interaction with p300 histone acetyltransferase blocks p300-mediated HSPA5 acetylation at K353, which promotes HSPA5 ubiquitination by GP78 and subsequent proteasome-mediated degradation . This represents a critical regulatory mechanism of HSPA5 in cancer metastasis.

What techniques are effective for studying HSPA5's RNA binding properties?

To investigate HSPA5's emerging role in RNA binding:

• RNA immunoprecipitation coupled to sequencing (RIP-Seq):

  • Use validated HSPA5 antibodies to immunoprecipitate RNA-protein complexes

  • Perform RNA sequencing on immunoprecipitated material

  • Analyze binding sites with peak calling algorithms

• Motif analysis:

  • Apply algorithms like HOMER to identify motif enrichment in coding sequences

  • Focus on AG-rich sequences like the AGAG motif, which has been identified in HSPA5-bound RNA

• Functional validation:

  • Assess effects of HSPA5 on alternative splicing using PCR-based splicing assays

  • Validate binding of HSPA5 to specific mRNAs like EGFR, NEAT1, LRP1, and TGFβ1, which are important in NAFLD pathology

• Structure-function correlation:

  • Design domain deletion constructs to identify RNA-binding regions of HSPA5

  • Perform in vitro binding assays with synthetic RNA oligonucleotides

Recent research has established that HSPA5 regulates pre-RNA alternative splicing, stability, or translation in an AG-rich sequence-dependent manner, particularly at 5'UTR and intronic regions .

How can I design experiments to study the relationship between HSPA5 and immune cell infiltration in tumors?

A comprehensive experimental approach should include:

• Multiplexed immunohistochemistry/immunofluorescence:

  • Co-stain for HSPA5 and immune cell markers

  • Quantify spatial relationships between HSPA5-expressing cells and immune infiltrates

  • Use digital pathology for unbiased quantification

• Single-cell RNA sequencing:

  • Analyze correlation between HSPA5 expression and immune cell signatures

  • Use TISCH-derived immune cell-related single-cell data

• Functional validation experiments:

  • Manipulate HSPA5 expression in tumor models and assess changes in immune infiltration

  • Use immune depletion studies to determine causality

• Correlation analysis with immune checkpoint molecules:

  • Analyze Spearman correlation between HSPA5 expression and immune checkpoint genes

  • Use TIMER algorithms for accurate immune score evaluation

Research has demonstrated that HSPA5 expression correlates with infiltration of various immune cells including aDCs, B cells, CD8 T cells, cytotoxic cells, DCs, eosinophils, iDCs, macrophages, mast cells, neutrophils, NK cells, and various T cell subtypes .

What is the optimal approach for using HSPA5 as a prognostic biomarker in cancer research?

Methodological considerations for HSPA5 prognostic studies:

• Multi-cohort validation strategy:

  • Analyze HSPA5 expression across multiple independent patient cohorts

  • Include diverse cancer types with sufficient sample sizes

  • Validate findings in external datasets like TCGA, GTEx, and GEPIA

• Comprehensive survival analysis:

  • Perform Kaplan-Meier survival analysis with log-rank tests

  • Use median HSPA5 expression as cutoff for high vs. low groups

  • Include multivariate analysis adjusting for clinical covariates

• Cancer stage-specific evaluation:

  • Stratify analysis by cancer stage and molecular subtypes

  • Compare expression patterns across different stages

  • Correlate with stage-specific survival outcomes

• Integration with other biomarkers:

  • Combine HSPA5 with other prognostic markers for improved accuracy

  • Develop prognostic scores incorporating HSPA5 expression

What methods are most effective for targeting HSPA5 in therapeutic research?

Advanced approaches for HSPA5-targeted therapy development include:

• Antibody-based therapeutic strategies:

  • Develop and test antibodies targeting cell surface HSPA5

  • Evaluate antibody-drug conjugates for selective targeting

  • Explore autoantibody-based approaches, as patients with prostate or ovarian cancer develop autoantibodies against extracellular HSPA5

• Small molecule inhibitor screening:

  • Target HSPA5 ATPase activity or substrate binding domains

  • Evaluate natural products with HSPA5-inhibiting properties

  • Test combination approaches with existing cancer therapies

• Genetic modulation approaches:

  • Use siRNA/shRNA-based HSPA5 knockdown

  • Evaluate CRISPR-based editing strategies

  • Explore antisense oligonucleotides targeting HSPA5 mRNA

• Dual-targeting strategies:

  • Simultaneously target HSPA5 and associated pathways

  • Combine with ER stress modulators

  • Target both cell surface and intracellular HSPA5 pools

Research indicates that targeting HSPA5 expression through natural products may have significance in clinical applications for both anti-COVID-19 and anti-cancer therapies . Additionally, since HSPA5 facilitates M2 macrophage polarization and lung tumor progression, targeting its immunomodulatory functions represents a promising approach .

How can the Hspa5 promoter be utilized in antibody production systems?

The Hspa5 promoter offers unique advantages for antibody production:

• Expression stability considerations:

  • Unlike conventional promoters (CMV, hEF1α) that decrease activity in late phase of fed-batch cell culture, the Hspa5 promoter maintains or increases expression throughout the culture period

  • This enables improved mAb productivity per cell in the late culture period

• Implementation methodology:

  • Clone the Hspa5 promoter upstream of antibody genes in expression vectors

  • Select stable CHO cell clones with integrated constructs

  • Validate expression kinetics throughout fed-batch culture

• Universal application potential:

  • The Hspa5 promoter improves productivity for various IgG subclasses

  • This indicates potential universal value for monoclonal antibody production

• Mechanism of action:

  • mAb production using the Hspa5 promoter correlates with transcription levels of endoplasmic reticulum stress-related genes

  • This suggests it maintains protein homeostasis during extended culture

Quantitative PCR experiments demonstrated that transcription levels of IgG genes under the control of the Hspa5 promoter were higher than those under the hEF1α promoter, particularly in late-stage cultures .

How can I resolve discrepancies between mRNA and protein levels of HSPA5 in experimental systems?

Methodological approaches to address mRNA-protein level discrepancies:

• Comprehensive analysis of post-transcriptional regulation:

  • Investigate mRNA stability using actinomycin D chase experiments

  • Analysis of HSPA5 mRNA half-life under various conditions

  • Examine microRNA-mediated regulation of HSPA5 translation

• Protein stability assessment:

  • Use cycloheximide chase assays to determine HSPA5 protein half-life

  • Investigate ubiquitination and proteasomal degradation pathways

  • Examine post-translational modifications affecting protein stability

• Transcriptional regulation analysis:

  • Perform chromatin immunoprecipitation to assess transcription factor binding

  • Analyze HSPA5 promoter activity using reporter assays

  • Investigate epigenetic modifications of the HSPA5 gene

Research has demonstrated that HSPA5 mRNA levels can decrease more rapidly than expected based on transcriptional inhibition alone, suggesting stimulated degradation mechanisms . For instance, HSPA5 mRNA levels decreased more than 30-fold between 8 hr and 24 hr in one study, despite having a measured half-life of 8.2 hours after transcriptional inhibition .

What are the critical considerations for HSPA5 antibody use in clinical sample analysis?

For reliable clinical sample analysis:

• Standardization protocols:

  • Establish consistent sample processing methods

  • Use automated staining platforms for reproducibility

  • Include reference standards in each batch

• Validation requirements:

  • Perform antibody validation on tissue microarrays representing target pathologies

  • Verify specificity in clinical samples with varying HSPA5 expression levels

  • Use multiple antibodies targeting different epitopes for confirmation

• Quantification methods:

  • Implement digital pathology for objective scoring

  • Use calibrated intensity measurements

  • Apply consensus scoring systems (e.g., H-score, Allred score)

• Pre-analytical variables control:

  • Document fixation time and processing methods

  • Control for ischemia time in surgical specimens

  • Account for tissue-specific expression patterns

Data from the Human Protein Atlas shows varying HSPA5 expression across tissues, with specific cell types showing differential expression. For example, in lung tissue, HSPA5 expression varies by cell type: pneumocytes (31.67%), endothelial cells (28.33%), macrophages (10.00%), bronchial epithelium (5.00%), and other cell types (25.00%) .

Human Protein Atlas data reveals HSPA5 consensus normalized expression of 43.6 NX units, with values of 247.6 pTPM (HPA), 275.1 pTPM (GTEx), and 449.0 Scaled Tags Per Million (FANTOM5) .

How can HSPA5 antibodies be used to study its role in pregnancy complications?

Methodological approach for investigating HSPA5 in pregnancy complications:

• Placental tissue analysis:

  • Use Western blot to validate HSPA5 protein levels in placental samples

  • Perform immunohistochemistry to determine cellular localization in trophoblasts

  • Apply immunoelectron microscopy for subcellular localization

• Functional studies in trophoblast cells:

  • Implement gene silencing of HSPA5 in trophoblast cell lines (e.g., HTR8/SVneo)

  • Assess effects on inflammatory response genes

  • Measure expression changes in proinflammatory cytokines

• Multi-level expression analysis:

  • Compare mRNA expression (qPCR) with protein levels

  • Investigate post-translational regulation mechanisms

  • Study correlations with clinical parameters

Research has demonstrated that HSPA5 is upregulated in placentas from spontaneous preterm births compared to term births, suggesting an association with premature labor . Interestingly, upregulation was not observed at the mRNA level, indicating post-translational regulation . Gene silencing experiments showed that HSPA5 affects the inflammatory response in trophoblast cells, potentially altering the anti-inflammatory state of the placenta .

What emerging techniques are enhancing HSPA5 research beyond traditional antibody applications?

Advanced methodologies expanding HSPA5 research capabilities:

• Proximity labeling approaches:

  • BioID or TurboID fusion proteins to identify HSPA5 interactors in living cells

  • APEX2-based labeling for temporally-controlled interaction mapping

  • Split-BioID systems to capture context-specific interactions

• Live cell imaging innovations:

  • CRISPR knock-in of fluorescent tags at the endogenous HSPA5 locus

  • Optogenetic control of HSPA5 localization and function

  • FRET/FLIM-based sensors to monitor HSPA5 conformational changes

• Single-molecule techniques:

  • Super-resolution microscopy to visualize HSPA5 distribution at nanoscale

  • Single-molecule tracking of HSPA5 dynamics

  • Optical tweezers to study HSPA5 chaperone function biophysically

• Integrative multi-omics approaches:

  • Combine transcriptomics, proteomics, and functional genomics

  • Use systems biology to model HSPA5 regulatory networks

  • Apply machine learning to predict HSPA5 function in different contexts